BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Huperzine A (SPN-817) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Huperzine A (SPN-817)\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT03474770-8879@assetmemo.bio
DTSTAMP:20261121T005952Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Huperzine A (SPN-817): Phase 1/2 readout est. (NCT03474770)
DESCRIPTION:Huperzine A (SPN-817)\, phase 1/2\, Epilepsy.\nStudy: BIS-001-E
 R for the Treatment of Adult Focal Impaired Awareness Seizures\nEstimated 
 primary completion: 30 December 2026. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/huperzine-a-spn-817#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT03474770
URL:https://assetmemo.bio/drug/huperzine-a-spn-817#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06798896-8879@assetmemo.bio
DTSTAMP:20261121T005952Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Huperzine A (SPN-817): Phase 2 readout est. (NCT06798896)
DESCRIPTION:Huperzine A (SPN-817)\, phase 2\, Epilepsy.\nStudy: RENAISSANCE
  2: SPN-817 Phase 2\, Double-Blind\, Placebo-Controlled Study in Adults Wi
 th Focal Onset Seizures\nEstimated primary completion: August 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/huperzine-a-spn-817#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06798896
URL:https://assetmemo.bio/drug/huperzine-a-spn-817#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05518578-8879@assetmemo.bio
DTSTAMP:20261121T005952Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Huperzine A (SPN-817): Phase 2 readout est. (NCT05518578)
DESCRIPTION:Huperzine A (SPN-817)\, phase 2\, Epilepsy.\nStudy: Safety and 
 Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant E
 pilepsy\nEstimated primary completion: 31 December 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/huperzine-a-spn-817#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT05518578
URL:https://assetmemo.bio/drug/huperzine-a-spn-817#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07141329-8879@assetmemo.bio
DTSTAMP:20261121T005952Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Huperzine A (SPN-817): Phase 2 readout est. (NCT07141329)
DESCRIPTION:Huperzine A (SPN-817)\, phase 2\, Epilepsy.\nStudy: SPN-817 Ope
 n-Label Extension Study in Adults With Focal Onset Seizures\nEstimated pri
 mary completion: 31 December 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/huperzine-a-spn-817#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07141329
URL:https://assetmemo.bio/drug/huperzine-a-spn-817#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
